natgillin/translations-raw huggingface dataset:
Darunavir was evaluated for carcinogenic potential by oral gavage administration to mice and rats up to 104 weeks. 
Karcinogeni potencijal darunavira procjenjivao se tijekom 104 tjedna, peroralnom primjenom darunavira kod miševa i štakora.
600 milligram 
600 miligrama
Polyvinyl alcohol, partially hydrolysed Titanium dioxide (E171) Macrogol 
Film ovojnica tablete poli(vinilni alkohol), djelomično hidroliziran titanijev dioksid (E171) makrogol talk
Darunavir Mylan 800 mg tablets is not for use in children younger than 3 years of age or weighing less than 40 kilograms. 
Darunavir Mylan 800 mg tablete nisu namijenjene za primjenu kod djece mlađe od 3 godine ili tjelesne težine manje od 40 kilograma.
atorvastatin Cmax ↑ 319% 
atorvastatin Cmax ↑ 319% Ω atorvastatin Cmin NO
Tablets of lower strengths are available and your doctor may have prescribed a certain combination of tablets to construct the appropriate dosing regimen. 
Dostupne su i tablete manjih jačina, pa Vam liječnik može propisati određenu kombinaciju tableta kojom će biti dosegnut odgovarajući režim doziranja.
Non-completer is failure imputation: patients who discontinued prematurely are imputed with a change equal to 0. 
Bolesnik koji nije završio ispitivanje ubilježen je kao neuspjeh: bolesnicima koji su prijevremeno prekinuli ispitivanje pripisana je promjena jednaka 0.
What you need to know before you take Darunavir Mylan 
Što morate znati prije nego počnete uzimati lijek Darunavir Mylan
When administration of atorvastatin and boosted darunavir is desired, it is recommended to start with an atorvastatin dose of 10 mg once daily. 
Kada se želi primijeniti atorvastatin i pojačani darunavir, preporučuje se početi s dozom atorvastatina od 10 mg jedanput na dan.
The dose of simeprevir in this interaction study was 50 mg when co-administered in combination with darunavir/ritonavir, compared to 150 mg in the simeprevir alone treatment group. 
Doza simeprevira u ovom ispitivanju interakcija bila je 50 mg kada se istodobno primjenjivao u kombinaciji s darunavirom/ritonavirom, u usporedbi sa 150 mg u skupini liječenoj samim simeprevirom.
Do not combine darunavir with products that contain St John's wort (Hypericum perforatum). 
Nemojte kombinirati darunavir s pripravcima koji sadrže gospinu travu (Hypericum perforatum).
Thyroid follicular cell adenomas were noted in male rats. 
Folikularni stanični adenom štitnjače zabilježen je kod muških štakora.
Patients should be instructed to take Darunavir Mylan with cobicistat or low dose ritonavir within 30 minutes after completion of a meal. 
Bolesnike se mora uputiti da uzimaju Darunavir Mylan s kobicistatom ili niskom dozom ritonavira unutar 30 minuta nakon završetka obroka.
The concomitant use with boosted darunavir may require to lower the dose of alfentanil and requires monitoring for risks of prolonged or delayed respiratory depression. 
Istodobna primjena s pojačanim darunavirom može zahtijevati snižavanje doze alfentanila i zahtjeva praćenje rizika za produljenu ili odgođenu respiratornu depresiju.
In-use shelf life after first opening HDPE bottle: 90 days. 
Rok valjanosti nakon prvog otvaranja boce od polietilena visoke gustoće (HDPE): 90 dana.
Therefore, darunavir must not be used in patients with severe hepatic impairment (Child-Pugh Class C) (see sections 4.3, 4.4 and 5.2). 
Stoga se darunavir ne smije primjenjivati u bolesnika s teškim oštećenjem jetre (Child-Pugh stadij C) (vidjeti dijelove 4.3, 4.4 i 5.2).
The effect of severe hepatic impairment on the pharmacokinetics of darunavir has not been studied (see sections 4.2, 4.3 and 4.4). 
Učinak teškog oštećenja jetre na farmakokinetiku darunavira nije ispitivan (vidjeti dijelove 4.2, 4.3 i 4.4).
Other severe side effects were diabetes (common), and inflammation of the pancreas (uncommon). 
Ostale teške nuspojave bile su šećerna bolest (često) i upala gušterače (manje često).
If you forget to take Darunavir Mylan 
Ako ste zaboravili uzeti lijek Darunavir Mylan
This should be taken into consideration if darunavir with cobicistat is administered to patients in whom the estimated creatinine clearance is used to adjust doses of co-administered medicinal products (see section 4.2 and cobicistat SmPC). 
Ovo se mora uzeti u obzir ako se darunavir s kobicistatom primjenjuje bolesnicima kod kojih se procijenjeni klirens kreatinina koristi za prilagodbu istodobno primijenjenih lijekova (vidjeti dijelove 4.2 i Sažetak opisa svojstava lijeka za kobicistat).
Number of subjects with virologic failurea and phenotype data that show resistance to PIs at endpointc, n/N 
Broj ispitanika s virološkim neuspjehom a i podaci o fenotipu koji pokazuju rezistenciju na IP na ishodu ispitivanjac, n/N
HIV-1 infected patients who were eligible for this trial had a screening genotype showing no darunavir RAMs and plasma HIV-1 RNA ≥ 1,000 copies/ml. 
Bolesnici inficirani s HIVom-1 koji u bili pogodni za ovo ispitivanje na probiru su imali genotip koji nije pokazivao RAM za darunavir i koncentracije HIV-1 RNK u plazmi ≥ 1000 kopija/ml.
- The other ingredients are colloidal anhydrous silica, cellulose microcrystalline, crospovidone, 
- Drugi sastojci su koloidni, bezvodni silicijev dioksid, mikrokristalična celuloza, krospovidon,
The evidence of efficacy of darunavir/ritonavir 800/100 mg once daily is based on the analyses of 192 week data from the randomised, controlled, open-label Phase III trial ARTEMIS in antiretroviral treatment-naïve HIV-1 infected patients comparing darunavir/ritonavir 800/100 mg once daily with lopinavir/ritonavir 800/200 mg per day (given as a twice-daily or as a once-daily regimen). 
Dokaz djelotvornosti darunavira/ritonavira 800/100 mg jedanput na dan temelji se na analizi podataka dobivenih nakon 192 tjedna randomiziranog, kontroliranog, otvorenog ispitivanja faze III pod nazivom ARTEMIS, provedenog u bolesnika inficiranih virusom HIV-1, prethodno neliječenih ART-om, u kojem se uspoređivao darunavir/ritonavir 800/100 mg jedanput na dan s lopinavir/ritonavir 800/200 mg na dan (primijenjena u režimu dva puta na dan ili jedanput na dan).
Medicinal products that may be affected by darunavir boosted with cobicistat The recommendations for darunavir boosted with ritonavir are adequate also for darunavir boosted with cobicistat with regard to substrates of CYP3A4, CYP2D6, P-glycoprotein, OATP1B1 and OATP1B3 (see contraindications and recommendations presented in the section above). 
Lijekovi na koje može utjecati darunavir pojačan s kobicistatom Preporuke za darunavir pojačan s ritonavirom vezano uz supstrate CYP3A4, CYP2D6, P glikoproteina, OATP1B1 i OATP1B3 primjenjive su također za darunavir pojačan s kobicistatom (vidjeti kontraindikacije i preporuke navedene u odjeljku iznad).
Co-administration of darunavir/cobicistat with weak to moderate CYP3A inducers (e.g. efavirenz, etravirine, nevirapine, boceprevir, fluticasone, and bosentan) is not recommended (see interaction table below). 
Ne preporučuje se istodobna primjena darunavira/kobicistata sa slabim do umjerenim induktorima CYP3A (npr. efavirenz, etravirin, nevirapin, boceprevir, flutikazon i bosentan) (vidjeti tablicu interakcija ispod).
Pharmacokinetic enhancer and concomitant medications Darunavir has different interaction profiles depending on whether the compound is boosted with ritonavir or cobicistat: - Darunavir boosted with cobicistat is more sensitive for CYP3A induction: concomitant use of darunavir/cobicistat and strong CYP3A inducers is therefore contraindicated (see section 4.3), and concomitant use with weak to moderate CYP3A inducers is not recommended (see section 4.5). 
Farmakokinetički pojačivači i istodobno primijenjeni lijekovi Profil interakcija darunavira različit je i ovisan o tome je li pojačan s ritonavirom ili s kobicistatom: - Darunavir pojačan s kobicistatom osjetljiviji je na CYP3A indukciju: stoga je kontraindicirana istodobna primjena darunavira/kobicistata i snažnih induktora CYP3A (vidjeti dio 4.3), te se ne preporučuje istodobna primjena sa slabim do umjerenim induktorima CYP3A (vidjeti dio 4.5).
During the darunavir/ritonavir clinical development program (N=3,063), hepatitis was reported in 0.5% of patients receiving combination antiretroviral therapy with darunavir/ritonavir. 
Tijekom kliničkog razvojnog programa darunavira/ritonavira (n=3063), hepatitis je prijavljen kod 0,5% bolesnika koji su primali kombiniranu antiretrovirusnu terapiju darunavirom/ritonavirom.
Based on the different elimination pathways of the other NRTIs zidovudine, emtricitabine, stavudine, lamivudine, that are primarily renally excreted, and abacavir for which metabolism is not mediated by CYP450, no interactions are expected for these medicinal compounds and darunavir coadministered with low dose ritonavir. 
Na temelju različitih puteva eliminacije drugih NRTI-ova, zidovudina, emtricitabina, stavudina, lamivudina, koji se primarno izlučuju putem bubrega, te abakavira čiji metabolizam nije posredovan CYP450, ne očekuju se interakcije ovih lijekova i darunavira primijenjenog istodobno s niskom dozom ritonavira.
Tell your doctor if you take: - Alfentanil (injectable strong and short-acting painkiller that is used for surgical procedures) - Digoxin (to treat certain heart disorders) - Clarithromycin (antibiotic) - Itraconazole, isavuconazole, fluconazole, posaconazole, clotrimazole (to treat fungal infections). 
Upozorite liječnika ako uzimate: - alfentanil (snažan lijek protiv bolova kratkotrajnog djelovanja, koji se primjenjuje u obliku injekcije kod operacija) - digoksin (za liječenje određenih srčanih poremećaja) - klaritromicin (antibiotik) - itrakonazol, izavukonazol, flukonazol, posakonazol, klotrimazol (za liječenje gljivičnih infekcija).
Not studied with darunavir/ritonavir. 
Nisu ispitani s darunavirom/ritonavirom.
When darunavir is coadministered with a drospirenone-containing product, clinical monitoring is recommended due to the potential for hyperkalaemia. 
Kada se darunavir istodobno primjenjuje s lijekovima koji sadrže drospirenon, preporučuje se kliničko praćenje zbog potencijalnog nastanka hiperkalemije.
When used in combination with darunavir co-administered with low dose ritonavir, dose adjustment of indinavir from 800 mg twice daily to 600 mg twice daily may be warranted in case of intolerance. 
Kada se darunavir primijeni istodobno s niskom dozom ritonavira u kombinaciji s indinavirom, može biti potrebna prilagodba doze indinavira s 800 mg dva puta na dan na 600 mg dva puta na dan u slučaju nepodnošljivosti.
sodium starch glycolate, hypromellose, magnesium stearate. 
natrijev škroboglikolat, hipromeloza, magnezijev stearat.
Darunavir Mylan 800 mg tablets are intended for once daily use only. 
Tablete Darunavir Mylan od 800 mg namijenjene su za uzimanje samo jednom dnevno.
Lidocaine (systemic) Mexiletine Propafenone 
Lidokain (sistemski) Meksiletin
POWER 1 and POWER 2 are randomised, controlled trials comparing darunavir co-administered with ritonavir (600/100 mg twice daily) with a control group receiving an investigator-selected PI(s) regimen in HIV-1 infected patients who had previously failed more than 1 PI containing regimen. 
U randomiziranim, kontroliranim ispitivanjima POWER 1 i POWER 2 uspoređivao se darunavir primijenjen istodobno s ritonavirom (600/100 mg dva puta na dan) s kontrolnom skupinom koja je primala režim IP prema izboru ispitivača u bolesnika inficiranih s HIV-1 koji su se pokazali neuspjeh u više od 1 režima s IP.
OTHER 
Drugoc
ART-experienced paediatric patients from the age of 6 to < 18 years, and weighing at least 20 kg 
Pedijatrijski bolesnici prethodno liječeni ART-om u dobi od 6 do < 18 godina i težine najmanje 20 kg
Mylan Hungary Kft Mylan utca 1, Komárom, 2900, Hungary 
Mylan utca 1, Komárom, 2900,
● In all other ART-experienced patients or if HIV-1 genotype testing is not available, the recommended dose regimen is 600 mg twice daily taken with ritonavir 100 mg twice daily taken with food. 
U svih ostalih bolesnika prethodno liječenih ART-om ili u slučaju nemogućnosti genotipizacije HIV-1, preporučeni režim doziranja je 600 mg dva puta na dan uz 100 mg ritonavira dva puta na dan, uzeto s hranom.
150 mg twice daily maraviroc AUC ↑ 305% maraviroc Cmin ND maraviroc Cmax ↑ 129% darunavir, ritonavir concentrations were consistent with historical data 
150 mg dva puta na dan maravirok AUC ↑ 305% maravirok Cmin ND maravirok Cmax ↑ 129% koncentracije darunavira, ritonavira bile su sukladne s podacima u anamnezi.
Co-administration with darunavir/ritonavir may cause a large increase in the concentration of these medicines. 
Istodobna primjena s darunavirom/ritonavirom može izazvati velik porast koncentracije tih lijekova.
Even if you feel better, do not stop taking darunavir and cobicistat or ritonavir without talking to your doctor. 
Čak i ako se osjećate bolje, ne prekidajte uzimati darunavir i kobicistat ili ritonavir bez da se posavjetujete sa svojim liječnikom.
- Take your other HIV medicines used in combination with darunavir and cobicistat or ritonavir as recommended by your doctor. 
- Ostale lijekove protiv HIV-a koje primjenjujete istodobno s darunavirom i kobicistatom ili ritonavirom, uzimajte prema preporuci Vašeg liječnika.
The exposure to total darunavir and ritonavir after intake of darunavir/ritonavir 600/100 mg twice daily and darunavir/ritonavir 800/100 mg once daily as part of an antiretroviral regimen was generally lower during pregnancy compared with postpartum. 
Ukupna izloženost darunaviru i ritonaviru nakon primjene darunavira/ritonavira 600/100 mg dva puta na dan i darunavira/ritonavira 800/100 mg jedanput dnevno kao dio antiretrovirusnog liječenja bila je općenito niža tijekom trudnoće u usporedbi s postpartalnim razdobljem.
Darunavir is not recommended for use in paediatric patients below 3 years of age or less than 15 kg body weight (see sections 4.2 and 5.3). 
Darunavir se ne preporučuje kod pedijatrijskih bolesnika mlađih od 3 godine starosti ili manje od 15 kg tjelesne težine (vidjeti dijelove 4.2 i 5.3).
For bottles: Once opened, use within 100 days. 
Za boce: Nakon otvaranja iskoristiti u roku od 100 dana.
Ear and labyrinth disorders Uncommon vertigo 
Poremećaji uha i labirinta manje često vertigo
Darunavir is used to treat adults and children of 3 years of age and above, and at least 15 kilogram body weight who are infected by HIV and who have already used other antiretroviral medicines. 
Darunavir se koristi za liječenje odraslih i djece u dobi od 3 godine i starije, tjelesne težine najmanje 15 kilograma, koji su zaraženi HIV-om te su prethodno liječeni drugim antiretrovirusnim lijekovima.
The metabolism of alfentanil is mediated via CYP3A, and may as such be inhibited by boosted darunavir. 
Metabolizam alfentanila posredovan je putem CYP3A, i kao takav može biti inhibiran pojačanim darunavirom.
Darunavir with ritonavir has not been tested with all PIs (protease inhibitors) and must not be used with other HIV PIs. 
Darunavir s ritonavirom nije bio ispitan sa svim IP (inhibitori proteaze) i ne smije se uzimati s drugim IP HIV-a.
During the darunavir/ritonavir clinical development program (N=3,063), severe skin reactions, which may be accompanied with fever and/or elevations of transaminases, have been reported in 0.4% of patients. 
Tijekom kliničkog dijela programa razvoja lijeka darunavir/ritonavir (n=3063), teške kožne reakcije, koje mogu biti praćene vrućicom i/ili povišenjima transaminaza, bile su prijavljene u 0,4% bolesnika.
DELPHI is an open-label, Phase II trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of darunavir with low dose ritonavir in 80 ART-experienced HIV-1 infected paediatric patients aged 6 to 17 years and weighing at least 20 kg. 
DELPHI je otvoreno ispitivanje faze II, koje procjenjuje farmakokinetiku, sigurnost, podnošljivost i djelotvornost darunavira s niskom dozom ritonavira kod 80 pedijatrijskih bolesnika prethodno liječenih ART-om inficiranih s HIV-1, u dobi od 6 do 17 godina i težine najmanje 20 kilograma.
Patients received a weight-based twice daily treatment regimen, patients weighing 10 kg to < 15 kg received darunavir/ritonavir 25/3 mg/kg twice daily, and patients weighing 15 kg to < 20 kg received darunavir/ritonavir 375/50 mg twice daily. 
Bolesnici su primili režim liječenja dva puta na dan ovisno o tjelesnoj težini, pri čemu su bolesnici tjelesne težine 10 kg do < 15 kg primili darunavir/ritonavir 25/3 mg/kg dva puta na dan, dok su bolesnici tjelesne težine 15 kg do < 20 kg primili darunavir/ritonavir 375/50 mg dva puta na dan.
If parenteral midazolam is coadministered with boosted darunavir, it should be done in an intensive care unit (ICU) or similar setting, which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. 
Ako se parenteralni midazolam istodobno primjenjuje s pojačanim darunavirom, primjena bi morala biti u jedinici intenzivnog liječenja ili sličnom odjelu gdje je osigurano pomno kliničko praćenje, te primjereno medicinsko zbrinjavanje u slučaju respiratorne depresije i/ili produljene sedacije.
ART-experienced adult patients 
Odrasli bolesnici prethodno liječeni ART-om
Caution should be used in pregnant women with concomitant medications which may further decrease darunavir exposure (see sections 4.5 and 5.2). 
Kod trudnica je potreban oprez s konkomitantnom terapijom koja može dodatno sniziti raspoloživost darunavira (vidjeti dijelove 4.5 i 5.2).
If a once daily dose of darunavir and/or cobicistat or ritonavir is missed within 12 hours of the time it is usually taken, patients should be instructed to take the prescribed dose of darunavir and cobicistat or ritonavir with food as soon as possible. 
U slučaju kad je doza darunavira i/ili kobicistata ili ritonavira koja se uzima jedanput na dan propuštena unutar 12 sati od uobičajenog vremena uzimanja, bolesnike se mora uputiti da propisanu dozu darunavira i kobicistata ili ritonavira uzmu s hranom što je prije moguće.
Rare insomnia depression, disorientation, anxiety, sleep disorder, abnormal dreams, nightmare, decreased libido confusional state, altered mood, restlessness 
Psihijatrijski poremećaji često manje često rijetko nesanica depresija, dezorijentiranost, anksioznost, poremećaj spavanja, nenormalni snovi, noćne more, smanjen libido stanje konfuzije, promijenjeno raspoloženje, nemir
Darunavir Mylan 400 mg film-coated tablets This medicinal product does not require any special storage conditions. 
Darunavir Mylan 400 mg filmom obložene tablete Lijek ne zahtijeva posebne uvjete čuvanja.
No treatment related mortalities were noted in juvenile rats dosed at 1,000 mg/kg darunavir (single dose) on day 26 of age or at 500 mg/kg (repeated dose) from day 23 to 50 of age, and the exposures and toxicity profile were comparable to those observed in adult rats. 
Nije bila zabilježena smrtnost uslijed liječenja mladih štakora pri dozi od 1000 mg/kg darunavira (jednokratna doza) na 26. dan starosti ili pri dozama od 500 mg/kg (ponovljene doze) od 23. do 50 dana starosti.
Flecainide 
Flekainid
If antidepressants are co-administered with boosted darunavir, the recommended approach is a dose titration of the antidepressant based on a clinical assessment of antidepressant response. 
Ako se antidepresivi primjenjuju istodobno uz pojačani darunavir, preporučeni pristup je titracija doze antidepresiva temeljeno na kliničkoj procjeni odgovora na antidepresiv.
≥ 1.0 log10 decrease from baseline in plasma viral load a 
≥ 1.0 log10 sniženje virusnog opterećenja plazme naspram početnih vrijednosti a
However, dizziness has been reported in some patients during treatment with regimens containing darunavir co-administered with cobicistat or low dose ritonavir and should be borne in mind when considering a patient's ability to drive or operate machinery (see section 4.8). 
Međutim, prijavljena je omaglica kod nekih bolesnika tijekom liječenja režimima koji su sadržavali darunavir primijenjen istodobno s kobicistatom ili niskom dozom ritonavira, što se mora imati na umu kada se procjenjuje bolesnikova sposobnost vožnje ili upravljanja strojevima (vidjeti dio 4.8).
If there is evidence of new or worsening liver dysfunction (including clinically significant elevation of liver enzymes and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver tenderness, hepatomegaly) in patients using darunavir/ritonavir, interruption or discontinuation of treatment should be considered promptly. 
Ako postoje dokazi o novoj ili pogoršanju disfunkcije jetre (uključujući klinički značajno povišenje enzima jetre i/ili simptomi poput umora, anoreksije, mučnine, žutice, tamne mokraće, osjetljivosti jetre, hepatomegalije) kod bolesnika koji uzimaju lijek darunavir/ritonavir, mora se odmah razmotriti privremeni ili trajni prekid liječenja.
The maraviroc dose should be 150 mg twice daily when coadministered with darunavir with low dose ritonavir. 
Doza maraviroka mora biti 150 mg dva puta na dan kada se primjenjuje istodobno s darunavirom u kombinaciji s niskom dozom ritonavira.
Darunavir Mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4.2): 
Tablete Darunavir Mylan od 75 mg, 150 mg, 300 mg i 600 mg mogu se primjenjivati da bi se osigurali prikladni režimi doziranja (vidjeti dio 4.2):
● In all other ART-experienced patients or if HIV-1 genotype testing is not available, the recommended dose regimen described in the Summary of Product Characteristics for darunavir 75 mg, 150 mg, 300 mg and 600 mg tablets. 
U svih ostalih bolesnika prethodno liječenih ART-om ili u slučaju nemogućnosti genotipizacije HIV-1, preporučeni režim doziranja je opisan u Sažetku opisa svojstava lijeka za darunavir 75 mg, 150 mg, 300 mg i 600 mg tablete.
Clinical monitoring is recommended when co-administering boosted darunavir with these sedatives/hypnotics and a lower dose of the sedatives/hypnotics should be considered. 
Preporučuje se kliničko praćenje kada se istodobno primjenjuje pojačani darunavir s tim sedativima/hipnoticima i u obzir treba uzeti nižu dozu sedativa/hipnotika.
These patients received darunavir 800 mg once daily in combination with cobicistat 150 mg once daily with an investigator selected background regimen consisting of 2 active NRTIs. 
Ovi bolesnici su primali darunavir 800 mg jedanput na dan u kombinaciji s kobicistatom od 150 mg jedanput na dan s osnovnim liječenjem koje je ukjučilo 2 aktivna NRTI-ja po izboru ispitivača.
Concomitant use of boosted darunavir and corticosteroids that are metabolised by CYP3A (e.g. fluticasone propionate or other inhaled or nasal corticosteroids) may increase the risk of development of systemic corticosteroid effects, including Cushing's syndrome and adrenal suppression. 
Istodobna upotreba pojačanog darunavira i kortikosteroida koje metabolizira CYP3A (npr. flutikazon propionat ili ostali inhalacijski ili nazalni kortikosteroidi) može povećati opasnost od razvoja sistemskih učinaka kortikosteroida uključujući Cushingov sindrom i adrenalnu supresiju.
Metabolism and nutrition disorders Common anorexia, diabetes mellitus, hypercholesterolaemia, hypertriglyceridaemia, hyperlipidaemia 
Poremećaji metabolizma i prehrane često anoreksija, dijabetes melitus, hiperkolesterolemija, hipertrigliceridemija, hiperlipidemija
ANTIMALARIALS Artemether/Lumefantrine 80/480 mg, 6 doses at 0, 8, 24, 36, 48, and 60 hours artemether AUC ↓ 16% artemether Cmin ↔ artemether Cmax ↓ 18% dihydroartemisinin AUC ↓ 18% dihydroartemisinin Cmin ↔ dihydroartemisinin Cmax ↓ 18% lumefantrine AUC ↑ 175% lumefantrine Cmin ↑ 126% lumefantrine Cmax ↑ 65% darunavir AUC ↔ darunavir Cmin ↓ 13% darunavir Cmax ↔ 
Lumefantrin 80/480 mg, 6 doza u 0., 8., 24., 36., 48. i 60. satu artemeter AUC ↓ 16% artemeter Cmin ↔ artemeter Cmax ↓ 18% dihidroartemisinin AUC ↓ 18% dihidroartemisinin Cmin ↔ dihidroartemisinin Cmax ↓ 18% lumefantrin AUC ↑ 175% lumefantrin Cmin ↑ 126% lumefantrin Cmax ↑ 65% darunavir AUC ↔ darunavir Cmin ↓ 13% darunavir Cmax ↔
When administration of atorvastatin and darunavir coadministered with low dose ritonavir is desired, it is recommended to start with an atorvastatin dose of 10 mg once daily. 
Kada se želi primijeniti atorvastatin i darunavir primijenjen istodobno s niskom dozom ritonavira, preporučuje se početi s dozom atorvastatina od 10 mg jedanput na dan.